Biogen Inc. (BIIB)Healthcare | Drug Manufacturers - General | Cambridge, United States | NasdaqGS
233.85 USD
-1.50
(-0.637%) ⇩
(Oct. 16, 2026, 3:31 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 11:42 a.m. EDT
Biogen's long-term outlook remains precarious despite a recent technical bounce. The cumulative return over the last nine years is a staggering 51.88% loss, reflecting a business that has struggled to maintain earnings growth, which has plummeted by 84.8% recently. While the forward P/E suggests a potential recovery, the lack of dividends and the persistent earnings contraction make this a poor candidate for a buy-and-hold strategy. In the short term, however, the stock is trading above its key moving averages, and options activity indicates traders are betting on a range between $200 and $250, offering a modest near-term opportunity for momentum plays. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.045812 |
| AutoARIMA | 0.058803 |
| AutoETS | 0.058872 |
| MSTL | 0.061488 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 50% |
| H-stat | 11.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.377 |
| Excess Kurtosis | -1.02 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 44.329 |
| Revenue per Share | 68.194 |
| Market Cap | 34,552,274,944 |
| Trailing P/E | 41.54 |
| Forward P/E | 14.16 |
| Beta | 0.09 |
| Profit Margins | 8.32% |
| Website | https://www.biogen.com |
As of Oct. 10, 2026, 11:42 a.m. EDT: Speculators are positioning for a range-bound outcome between $200 and $250. Call buyers are targeting upside to $240-$250, while put buyers are heavily defending the $200-$205 level. Implied volatility is elevated at deep strikes, suggesting fear of a sharp move in either direction.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.64580417 |
| Address1 | 225 Binney Street |
| All Time High | 480.18 |
| All Time Low | 0.354167 |
| Ask | 245.27 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 1,222,170 |
| Average Daily Volume3 Month | 993,145 |
| Average Volume | 993,145 |
| Average Volume10Days | 1,222,170 |
| Beta | 0.092 |
| Bid | 223.72 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 127.61 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 233.85 |
| Current Ratio | 1.865 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 236.74 |
| Day Low | 232.481 |
| Debt To Equity | 44.329 |
| Display Name | Biogen |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,217,600 |
| Earnings Call Timestamp Start | 1,793,217,600 |
| Earnings Growth | -0.848 |
| Earnings Quarterly Growth | -0.846 |
| Earnings Timestamp | 1,793,190,600 |
| Earnings Timestamp End | 1,793,190,600 |
| Earnings Timestamp Start | 1,793,190,600 |
| Ebitda | 3,359,200,000 |
| Ebitda Margins | 0.33499 |
| Enterprise To Ebitda | 12.457 |
| Enterprise To Revenue | 4.173 |
| Enterprise Value | 41,844,002,816 |
| Eps Current Year | 12.52784 |
| Eps Forward | 16.52024 |
| Eps Trailing Twelve Months | 5.63 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 219.1812 |
| Fifty Day Average Change | 14.668808 |
| Fifty Day Average Change Percent | 0.06692549 |
| Fifty Two Week Change Percent | 64.580414 |
| Fifty Two Week High | 240.99 |
| Fifty Two Week High Change | -7.1399994 |
| Fifty Two Week High Change Percent | -0.029627781 |
| Fifty Two Week Low | 138.0 |
| Fifty Two Week Low Change | 95.850006 |
| Fifty Two Week Low Change Percent | 0.69456524 |
| Fifty Two Week Range | 138.0 - 240.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 685,114,200,000 |
| Float Shares | 147,219,129 |
| Forward Eps | 16.52024 |
| Forward P E | 14.155363 |
| Free Cashflow | 1,266,987,520 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 7,500 |
| Fullday Change | -1.5 |
| Fullday Change Percent | -0.6373486 |
| Fullday Price | 233.85 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.78322 |
| Gross Profits | 7,854,099,968 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0018799999 |
| Held Percent Institutions | 0.99634004 |
| Implied Shares Outstanding | 147,753,998 |
| Industry | Drug Manufacturers - General |
| Industry Disp | Drug Manufacturers - General |
| Industry Key | drug-manufacturers-general |
| Ir Website | http://www.biogenidec.com/INVESTORS.aspx?ID=5494 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 979,776,000 |
| Last Split Factor | 3:1 |
| Long Business Summary | Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Biogen Inc. |
| Market | us_market |
| Market Cap | 34,552,274,944 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_29726 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 834,600,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 33,618,467,164 |
| Number Of Analyst Opinions | 32 |
| Open | 235.77 |
| Operating Cashflow | 2,878,799,872 |
| Operating Margins | 0.25058 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.4 |
| Phone | 617 679 2000 |
| Previous Close | 235.35 |
| Price Eps Current Year | 18.666428 |
| Price Hint | 2 |
| Price To Book | 1.8325367 |
| Price To Sales Trailing12 Months | 3.4456143 |
| Profit Margins | 0.083229996 |
| Quick Ratio | 0.94 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.83333 |
| Region | US |
| Regular Market Change | -1.5 |
| Regular Market Change Percent | -0.6373486 |
| Regular Market Day High | 236.74 |
| Regular Market Day Low | 232.481 |
| Regular Market Day Range | 232.481 - 236.74 |
| Regular Market Open | 235.77 |
| Regular Market Previous Close | 235.35 |
| Regular Market Price | 233.85 |
| Regular Market Time | 1,792,179,094 |
| Regular Market Volume | 905,446 |
| Return On Assets | 0.052059997 |
| Return On Equity | 0.04575 |
| Revenue Growth | 0.034 |
| Revenue Per Share | 68.194 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 147,753,998 |
| Shares Percent Shares Out | 0.0404 |
| Shares Short | 5,965,892 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,726,631 |
| Short Name | Biogen Inc. |
| Short Percent Of Float | 0.045 |
| Short Ratio | 5.89 |
| Source Interval | 15 |
| State | MA |
| Symbol | BIIB |
| Target High Price | 300.0 |
| Target Low Price | 175.0 |
| Target Mean Price | 243.97906 |
| Target Median Price | 243.5 |
| Total Cash | 1,284,999,936 |
| Total Cash Per Share | 8.697 |
| Total Debt | 8,355,100,160 |
| Total Revenue | 10,027,899,904 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 5.63 |
| Trailing P E | 41.53641 |
| Trailing Peg Ratio | 2.3453 |
| Triggerable | 1 |
| Two Hundred Day Average | 197.5473 |
| Two Hundred Day Average Change | 36.302704 |
| Two Hundred Day Average Change Percent | 0.18376714 |
| Type Disp | Equity |
| Volume | 905,446 |
| Website | https://www.biogen.com |
| Zip | 2,142 |